He Jiankui’s Genetic Misadventure, Part 2: How Different Are Chinese and Western Bioethics?
By Jing-Bao Nie, Neil Pickering,
Hastings Bioethics Forum
| 12. 13. 2018
When the world’s first research on editing the genes of human embryos by Chinese scientists was published in an international journal in 2015, a report in the New York Timescharacterised the key issue involved as “a scientific ethical divide between China and West.” Earlier this year, an article in the magazine Foreign Policy by a researcher with Chinese origin put it bluntly that “China will always be bad at bioethics.” Now, He Jiankui’s announcement on gene-edited babies appears to provide more compelling evidence that China is the “radical other” of the West, a wild land where bioethics matters little.
Is this really the right way to look at things? Our answer is, no. The evidence doesn’t bare these beliefs out; it is a misdiagnosis, and it risks obscuring the real issues that He Jiankui’s experimentation raises. Since the news on the gene-edited babies came out on November 26 via Baidu and Google, one of us (Nie) has been closely following reactions to it in journalists’ reports, commentaries, and posts on Chinese and international mass media, as well as on...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...